Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission

Final histology and laboratory analyses support the study’s safety and performance objectives

THE WOODLANDS, TX, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion of its Good Laboratory Practice (GLP) pre-clinical study, a significant regulatory milestone supporting the Company's submission to the U.S. Food and Drug Administration (FDA).